Opaganib Receives FDA Rare Pediatric Disease Designation, Opening Path to Valuable Priority Review Voucher
RDHL sits 82% above its 52-week low of $0.71 on elevated volume (2.3× avg).
Summary
RedHill Biopharma's drug candidate, Opaganib, has received FDA Rare Pediatric Disease Designation (RPDD) for neuroblastoma, adding to its existing Orphan Drug Designation. This follows a 6-K filing earlier today confirming the designation. The RPDD makes Opaganib eligible for a Priority Review Voucher (PRV) upon FDA approval, which could be a significant non-dilutive funding source for the company. This is a major positive regulatory development, especially given the company's recent Nasdaq delisting notice and 'going concern' warning.
At the time of this announcement, RDHL was trading at $1.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.3M. The 52-week trading range was $0.71 to $3.31. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.